2 completed, 1 active not recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Atrogi AB: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GRK-Biased Activation Via β2-Adrenergic Receptors in Human Skeletal Muscle ATR-258 - Overweight and Obesity | Phase 2 | Active not recruiting | Morten Hostrup, PhD | 13 | 2026-02-19 | 2026-10-14 |
| The Attractive 2 Trial - Pharmacokinetics of ATR-258 Oral Capsule vs. Oral Solution Formulations in Healthy Volunteers ATR-258 Oral solution, ATR-258 Oral capsule - Type2diabetes | Phase 1 | Completed | Atrogi AB | 21 | 2024-04-24 | 2024-07-01 |
| First-in-human Single and Multiple Dose Trial of ATR-258 ATR-258 - Type 2 Diabetes Mellitus | Phase 1 | Completed | Atrogi AB | 71 | 2022-04-11 | 2023-12-18 |
Diabetes Mellitus, Type 2 (2) · Obesity (1) · Overweight (1)
Denmark (1) · Germany (1) · Sweden (1)
Erik Waara (1)
2023 (1)